SYT15B promotes tumor progression through interaction with IQGAP1 to activate the MAPK pathway in lung adenocarcinoma
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2025.112302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Yue Ren und 12 weiteren Autor:innen. Beteiligte Einrichtung: Yangzhou University Medical College, Yangzhou, China; Department of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou, China. Hauptthemen laut MEDLINE: ras GTPase-Activating Proteins, Adenocarcinoma of Lung, Lung Neoplasms, MAP Kinase Signaling System. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, National Natural Science Foundation of China, High Level Innovation and Entrepreneurial Research Team Program in Jiangsu.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) the predominant subtype of lung cancer, is characterized by rapid tumor growth, local invasion, and distant metastasis. Since dysregulated expression of synaptotagmin (SYT) proteins have been implicated in the development and progression of LUAD, the specific role and mechanisms of SYT15B in LUAD remain unclear. This study demonstrates that elevated SYT15B expression drives malignant progression and predicts poor prognosis in LUAD, as evidenced by integrated clinical sample, in vitro, and in vivo analyses. We identify a novel molecular mechanism whereby SYT15B interacts with IQ motif-containing GTPase-activating protein 1 (IQGAP1), leading to activation of the MAPK signalling pathway and subsequent promotion of aggressive tumor phenotypes. Disruption of the SYT15B-IQGAP1 interaction through IQGAP1 knockdown attenuated MAPK signalling pathway activation and reversed the oncogenic phenotype induced by SYT15B. Notably, specific inhibition of intracellular calcium with BAPTA can also attenuates SYT15B-IQGAP1 complex formation, abrogates MAPK signalling activation, and reverses SYT15B-mediated oncogenic effects. These findings establish the calcium-dependent SYT15B/IQGAP1/MAPK axis as a potential therapeutic and prognostic biomarker in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yangzhou University Medical College, Yangzhou, China; Department of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
- Yangzhou University Medical College, Yangzhou, China; School of Public Health, Yangzhou University, Yangzhou, China.
- Department of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
- Yangzhou University Medical College, Yangzhou, China; Clinical College of Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
- Yangzhou University Medical College, Yangzhou, China.
- Department of Pathology, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Förderung
- Graduate Research and Innovation Projects of Jiangsu Province
- National Natural Science Foundation of China
- High Level Innovation and Entrepreneurial Research Team Program in Jiangsu
- Yangzhou University
Zitieren
APA
Ren, Y., Li, T., Zhou, H., Cui, Y., Li, C., Shen, W., Sun, H., Mao, H., Zhang, Z., Wang, Z., Ling, Z., Chen, Y., & Yin, X. (2026). SYT15B promotes tumor progression through interaction with IQGAP1 to activate the MAPK pathway in lung adenocarcinoma. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112302
Vancouver
Ren Y, Li T, Zhou H, Cui Y, Li C, Shen W, et al. SYT15B promotes tumor progression through interaction with IQGAP1 to activate the MAPK pathway in lung adenocarcinoma. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2025.112302
BibTeX
@article{Ren2026,
author = {Ren, Yue and Li, Tianyi and Zhou, Heng and Cui, Yuqing and Li, Chenghao and Shen, Weigan and Sun, Haibo and Mao, Haiyan and Zhang, Zhengrong and Wang, Zheng and Ling, Zhi and Chen, Yong and Yin, Xudong},
title = {SYT15B promotes tumor progression through interaction with IQGAP1 to activate the MAPK pathway in lung adenocarcinoma},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2025.112302}
}
EUVIMED